BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $137.00. The company’s shares closed last Friday at $99.72. Don't ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

Analysts fell to the sidelines weighing in on BioNTech SE (BNTX – Research Report) and Idexx Laboratories (IDXX – Research Report) with neutral ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

Shares of BioNTech (BNTX) gained in pre-market trading after the company reported better-than-expected Q3 earnings. The biotech company’s earnings increased by 22.7% to €0.81 ($0.89 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...